Bevacizumab for the first-line treatment of metastatic breast cancer

NICE technology appraisals [TA147] Published date:

This guidance has been replaced by TA214, February 2011, ‘Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer'.

Get involved